Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish
population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R
agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests
(FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific
aims:
1. Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist
to enhance glucose-stimulated first phase insulin secretion in the two FSIGTs (before
and after administration of drug).
2. Specific Aim #2. To identify genetic variants associated with the effect of a GLP1R
agonist to accelerate the rate of glucose disappearance as assessed in the two FSIGTs
(before and after administration of drug).
Genotyping will be conducted using a high-density array with comprehensive coverage of DNA
sequence variants. In addition, the analysis will leverage a global imputation panel
generated from 1,025 Amish individuals.
Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
Not yet recruiting
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
2022-05-01
This is a randomized placebo-controlled trial of semaglutide, an FDA-approved therapy for the
treatment of type 2 diabetes mellitus and obesity, in adults with symptomatic asthma despite
the use of inhaled steroids and with excess body weight. We will test the central hypothesis
that semaglutide will improve asthma control and reduce airway inflammation due to direct
effects on the respiratory tract in adult asthma associated with obesity.
Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
Not yet recruiting
Vanderbilt University Medical Center
Phase 2
2022-05-01
This is a randomized placebo-controlled trial of semaglutide, an FDA-approved therapy for the
treatment of type 2 diabetes mellitus and obesity, in adults with symptomatic asthma despite
the use of inhaled steroids and with excess body weight. We will test the central hypothesis
that semaglutide will improve asthma control and reduce airway inflammation due to direct
effects on the respiratory tract in adult asthma associated with obesity.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
